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Micro RNAs (miRNAs) are 19-24 nucleotide long non-coding RNAs that posttranscriptionally modulate gene 
expression. They are found in almost all species: viruses, plants, nematodes, fly, fish, mouse, human, and are 
implicated in a wide array of cellular and developmental processes. Microarray-based miRNA profiling brought 
to the discovery of miRNAs specific to different hematopoietic lineages. Furthermore, the functional assays 
performed in tissue cultures to discover miRNAs involved in immune responses in combination with the reports 
of miRNA-transgenic or miRNA-knockout mouse models has helped elucidating the miRNA roles in the 
development and function of immune system. Abnormal patterns of hematopoietic-specific miRNAs have been 
found in different types of cancer and miRNA based gene therapy is being considered as a potential technology 
of choice in immunological disorders and cancer. The purpose of this review is to discuss recent findings related 
with the expression and function of miRNAs in hematopoietic lineages. 
Key words: Acquired immune response; Cancer; Cytokines; Drug discovery; Hematopoietic lineage; Innate immune 
response; TNF-α. 
Introduction 
Since their discovery, micro RNAs (miRNAs) 
have been implicated in a wide array of cellular and 
developmental processes [1]. In particular, they are 
key players in the regulation of translation or 
degradation of target mRNAs through base pairing to 
partially complementary sites. Their number 
over-passed 500 and more miRNAs are getting cloned 
or in silico identified. Parallel to miRNA identification, 
genetic studies addressing their physiological roles in 
vivo in complement to different functional assays has 
brought a lot of information about their critical role in 
almost all the aspects of cell biology [2]. It has now 
been demonstrated that miRNAs are involved in 
establishment, maintenance, and function of 
hematopoietic lineages (see below), establishment of 
muscle phenotype such as miR-1,  -133,  -206 -208, or 
regulation of organogenesis such as miR-1-2 or 
miR-133  [3]. They are also involved in metabolic 
processes and metabolic diseases such as miR-9, 
miR-143 or miR-122, neuronal function and 
neurological disorders, ageing, fragile X syndrome and 
hypoxia (for a thorough review on the roles of 
miRNAs in different biological processes and cancer 
refer to the review by Tili et al., [3]). Expression of some 
of the miRNAs is mostly restricted to a single tissue or 
organ as e.g. miR-142 in lymphoid tissue, miR-223 in 
myeloid tissue or miR-1-2 in muscle [3]. The majority 
of miRNAs are widely expressed. Abnormal patterns 
of miRNA expression have been found in all the 
examined disease states, especially cancers (for a 
review on abnormal expression and function of 
miRNAs in cancer consult the reviews by Calin & 
Croce [4] and Esquela-Kershner & Slack [5]). Extensive 
genome-wide expression profiling of cells and tissues 
in different stages of development or differentiation, 
metabolic conditions, and disease models using 
miRNA-specific microarrays brought to the conclusion 
that unique miRNA profiles exist that are specific for 
the studied types of samples. These exciting but 
unexpected findings crystallized the hypothesis that 
genome-wide miRNA expression profiling could be 
used to profile tumors based on their origin and 
differentiation state, to help in diagnostic, prognosis, 
and for the use of miRNAs in therapeutic. 
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BIOGENESIS AND MECHANISMS OF 
ACTION OF miRNAs 
Primary miRNA transcripts (pri-miR) are 
processed into precursor miRNA (pre-miRNA) by an 
enzymatic complex that includes the nuclear RNAse III 
enzyme Drosha and DGRC8 (Digeorge syndrome 
critical region gene 8). The resulting pre-miRNA is 
next transported to the cytoplasm by Exportin-5 and a 
RAS-like nuclear protein–guanosine triphosphate 
GTP, RAN. Once in cytoplasm pre-miRNA are 
processed into mature 22-nucleotide duplexes by 
another RNAse III enzyme, Dicer in association with 
TRBP (HIV-transactivating response RNA-binding 
protein). Only one of the strands of miRNA duplex is 
loaded onto the RNA-induced silencing complex 
-RISC. The mature miRNA binds then the 3’ 
untranslated region of target mRNA transcripts and 
either destabilizes the target mRNA transcript, blocks 
its translation or both. The miRNA:mRNA recognition 
is mediated by complementary binding between the 5’ 
end of the miRNA referred to as the miRNA “seed” 
region and the corresponding complementary 
sequence in the mRNA target [1, 2, 6]. Although the 
binding of miRNAs to its target mRNA blocks the 
translation, a few recent reports have brought evidence 
that miRNAs might activate or enhance translation [7, 
8]. In silico bioinformatics analyses has helped a lot in 
predicting the potential targets of miRNAs. 
Elucidating miRNA-target genes and their mechanism 
of action has given valid clues in understanding the 
physiological role of miRNAs in vivo, and is paving the 
platform for future use of miRNAs as therapeutic 
tools. 
miRNAs SPECIFICALLY INVOLVED IN 
THE DIFFERENTIATION OF 
HEMATOPOIETIC LINEAGES 
Chen et al., [9] and Monticelli et al., [10] analyzed 
miRNA expression profiles of different types of 
hematopoietic cells in murine and human respectively. 
They reported that miRNA expression patterns were 
very different not only between hematopoietic and 
non-hematopoietic cells but also within the 
hematopoietic group. Both reports are the first to show 
that miRNAs are implicated in the commitment of 
hematopoietic stem cells to a particular cell lineage. 
These reports together with a previous report by Calin 
et al., [11] stating that miRNA expression profiles can 
be used to characterize human tumors confirmed the 
use of miRNA expression profiles as tool to 
characterize the hematopoitic-lineage specific cells, 
stage specific cells or lymphoma/leukemic cells. 
Parallel to miRNA profiling studies, ectopic expression 
of miRNAs in hematopoietic stem cells substantially 
altered lineage differentiation giving thus strong 
evidence that miRNAs are not only differentially 
expressed in hematopoietic lineages but they also 
direct physiologically these processes [12]. In addition 
to regulating hematopoietic-cell lineage 
differentiation, it was found that miRNAs play an 
important role in innate immune response and 
adaptive immune responses in mice (see below). 
Another important observation to be mentioned is the 
fact that miRNA levels are altered by different 
cytokine stimulation in immune cells. Thus, miR-125b 
and miR-155 levels oscillated within an hour of TNF-α 
stimulation in mouse Raw 264.7 cells [7]. Furthermore 
this oscillation paralleled the rapid increase and 
subsequent decrease in NF-κB transcriptional activity 
[7]. Fast increase of cellular miRNAs levels was also 
reported in response to INFβ  [13]. Whether these 
changes are specific to the immune cells as a way to 
limit the level and duration of the immune response to 
infections before it becomes detrimental to the health 
of the organism or are a common feature of other cells 
remains to be evaluated. Furthermore there is a 
dynamic change in the levels of miRNAs within the 
same cell type but in different activation state. 
Combined analyses using direct cloning of miRNAs, 
microarray profiling and RT-PCR, was used to identify 
miRNA expression profile in antigen specific naïve, 
effectors and memory CD8 T cells. The study brought 
the discovery of dynamic regulation of miRNAs 
during antigen-induced CD8 T cell differentiation. 
miR-16, -142-3p, -142-5p, -150, -15b and let-7f were 
downregulated in effector cells compare to naïve cells 
and increased back in memory T cells [14]. Effector T 
cells originate from naïve T cells following antigen 
exposure and are considered cells in a high state of 
activity. It is interesting to emphasize the fact that the 
global downregulation of miRNAs in activated T cells 
looks similar with global downregulation of miRNA 
expression observed in some cancer cells [4]. We will 
next describe a few miRNAs found to be specific to 
hematopoietic lineages (Figure 1) and their 
corresponding targets (Table 1) that seem to be crucial 
in development and function of the immune response. 
In addition we will discus their abnormal patterns of 
expression associated with cancer and why 
m a n i p u l a t i n g  t h e i r  l e v e l s  o f  e x p r e s s i o n  i s  s u c h  a  
promising method in the fight against cancer and 
immunological disorders.  
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Figure 1. miRNAs involved in hematopoietic differenciation and function. Blood cells derive from a common hematopoietic 
stem cell progenitor (HSP) which differenciate into at least 8 lineages, through progenitor cells. For simplicity, the progenitor cells 
are not shown and only four of the main hematopoitic lineages are depicted. miRNAs that are reported to be involved in the 
differentiation of the shown lineages based on the mouse models are noted. Consult the text for further details. 
 
Table 1. miRNAs implicated in the development and function of the immune system 
 
 
miR-155 
MiR-155 is a product of BIC (B cell integration 
cluster) transcript, and has been shown to be 
upregulated in many types of B cell lymphoma, diffuse 
large B‑cell lymphomas, Hodgkin lymphomas, and 
Burkitt lymphomas [3-5]. BIC transcript was first 
identified as a frequent site of integration for the avian 
leucosis virus, and its coexpression with c-Myc have 
synergizing effects in lymphomagenesis [15]. 
Costinean  et al., [16] developed the first transgenic 
mouse that specifically overexpresses miR-155 in B 
cells, thus modeling the human B cell leukemia where 
the upregulation of miR-155 is observed. The 
transgenic mice developed polyclonal pre-leukaemia 
B-cell type followed by B-cell malignancy. Mice 
knockout for bic/mir‑155 gene are viable but they are 
unable to develop a proper immune T-, B-, or dentritic- 
dependent response [17, 18]. Upregulation of miR-155 
levels were also reported in human monocytes and 
mouse macrophages in response to LPS or interferon 
[7, 19]. Detailed analyses of the function of miR-155 in 
B cells revealed that this miRNA plays a key role in Int. J. Med. Sci. 2008, 5 
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antigen-driven B cell maturation and the persistence 
and/or differentiation of Ig class-switched cells and 
that deregulation of Pu.1 is among the factors 
responsible for the phenotypes observed in miR-155 
deficient mice [20]. Pu.1 is a member of the Ets 
domain-transcription factor family that plays a central 
role in many aspects of hematopoesis. Another 
exciting discovery for the function of this miRNA in 
the innate immune response was that it enhances 
TNF-α translation [7]. It was among the first reports 
suggesting that although miRNAs negatively regulate 
the translation of target transcripts it is possible that 
they might enhance in specific instances translation. A 
later publication experimentally confirmed the 
hypothesis.  [8]. Thus, Vasudevan et al., [8] reported 
that when cultured mammalian cells are 
serum-starved, binding of miR-369-3 to a reporter 
mRNA (containing the TNF- 3′UTR) enhanced 
translation, whereas no stimulation was observed 
when this miRNA is absent. Interestingly, miR-369-3 
repressed translation on actively dividing cells. It is 
still very early to draw any conclusion on the 
molecular mechanisms or cellular settings that 
promote the enhancement of translation by miRNAs 
and what are the elements that make this switch. Thai 
et al., [17] also  demonstrated that miR‑155 might 
control the formation and response of germinal-centre 
B cells in part by controlling cytokine production. E.g. 
miR-155-deficient mice, showed weak production of IL
‑ 2, IL‑ 4 and IFNγ by activated T cells [17] while the 
miR-155 transgenic mice overproduced TNF-α when 
challenged with LSP [7]. miR-155 expression is 
modulated by antigenic stimulation in B cells, TNF-α 
in macrophages, or other Toll like receptor ligands [7, 
17-20]. It is still not very clear the role of NF-κB in 
regulation on miR-155 expression. Putative binding 
sites for NF-κB family members are found in human 
and mouse promoter regions of BIC. It is possible that 
this miRNA is transiently under the transcriptional 
control of NF-κB activity [7]. In addition high levels of 
miR-155 were reported by Rai et al., [21] in diffuse large 
B-cell lymphoma characterized by constitutive 
activation of NF-κB signals. Interestingly, it was 
reported that miR-155 levels oscillate in a pattern 
similar to NF-κB activity [7]. Whether it is the miR-155 
levels that control the activity of NF-κB in this situation 
or is the NF-κB activity that results in the oscillatory 
levels of miR-155 r e m a i n s  t o  b e  s h o w n .  O v e r a l l  
knockout and transgenic mouse models developed for 
miR-155 proved that this miRNA plays a central role in 
innate and acquired immune response. Elucidating the 
mechanisms by which miR-155 expression is controlled 
and finding its targets will bring more understanding 
of the mechanisms of tumor induction by miR-155.  
miR-181 
miR-181 is highly expressed in the thymus as well 
as the brain, lung, bone marrow and spleen [9, 10]. 
This miRNA has been shown to regulate T and B cell 
development when ectopically expressed in 
hematopoietic progenitor cells [9]. The first report that 
suggested that this miRNA might play a role in the 
development of T cell lineage came from the elegant 
work proving that the expression levels of this miRNA 
change dynamically during thymocyte differentiation 
implying also that miR-181 might be important for not 
only T cell development but also for T cell function 
[22]. Indeed latter it was shown that the levels of 
miR-181 correspond with the sensitivity of T cells to 
antigens  [23]. In normal conditions, the successful 
transition of double positive thymocytes to the single 
positive stage depends on positive and negative 
selection processes that take place in the thymus. 
Positive and negative selection, ensure that only those 
thymocytes expressing a repertoire of antigen 
receptors that can respond to foreign antigens, but not 
to self, will survive. Phosphatases play a critical role in 
the generation of the thymocyte repertoire because 
they negatively control the response of T cells to 
antigens. Increasing levels of miR-181 resulted in 
higher sensitivity of T cells to antigens, while the 
opposite was observed when miR-181  levels were 
diminished [23]. These results translate in a central role 
for miR-181 in positive and negative thymic selection, 
both processes depending on the strength of the 
signals generated by T cell receptor (TCR). miR‑181 
effects on TCR signaling was found to be due to 
targeting by miR-181 of multiple phosphatases, such as 
SHP2, PTPN22, DUSP5 and DUSP6 [23]. By 
modulating T‑cell sensitivity to antigens, miR-181 
therefore, plays a central role in the development and 
maintenance of tolerance and immune T cells. Finally, 
miR-181 family is considered oncogenic. 
Overexpression of miR-181  is observed in breast, 
pancreas and prostate cancers [4]. This oncogenicity 
might be explained by targeting of Tcl1 [24] or Hox 
[25] transcripts in addition to phosphatases. It is 
proposed that at the transcriptional level this miRNA 
is under the activity of MYCN [26].  
miR-150 
miR-150, is mainly expressed in the lymph nodes 
and spleen and is highly up-regulated during the 
differentiation of mature T and B cells suggesting that 
it may participate in B and/or T lymphopoiesis [27]. 
When ectopically expressed in hematopoietic stem cell 
progenitors,  miR‑150 blocked B cell development at 
the transition pro-B to pre-B-cell stage, impairing the 
maturation of B cells, while moderately enhancing T Int. J. Med. Sci. 2008, 5 
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lymphopoiesis and myelopoiesis from hematopoietic 
stem and progenitor cells [28]. As expected from the 
above studies, miR-150-knockout mice have a double 
increase in the number of B- splenocytes, but have no 
apparent defects in the development of other 
lymphocytes. Like for miR-155 the expression of miR‑
150 is modulated by triggering B cells with 
IgM-specific antibodies, CpG-containing DNA or LPS 
[28]. Regarding its abnormal expression in disease 
state miR-150 is found to be differentially expressed in 
certain types of cancers [29].  
miR -125b and miR-146 
miR-146 is expressed at low levels in naïve T cells 
and is upregulated in Th1 cells, but not in Th2 cells 
[10]. Based on this miR-146 is a considered as Th1 
specific miRNA. miR-146  and  miR-132 levels were 
reported to be upregulated in human monocytes in 
response to LPS [19], while the levels of miR-125b were 
downregulated in murine macrophages following the 
same stimuli [7]. Upregulation of miR-146 in response 
to LPS was seen as a mean to negatively regulate the 
innate immune response, while the downregulation of 
miR-125b as a necessary step to allow TNF-α 
production due to the fact that this miRNA targets 
TNF-α transcripts [7, 19]. Downregulated levels of 
miR-125b where also observed in psoriasis, a skin 
inflammatory disease associated with high levels of 
TNF-α [30]. 
Let-7 
Let-7 was among the first miRNAs identified in C. 
elegance. The let-7 gene family has been evolutionarily 
expanded from one member in nematodes to 11 
members in mice and humans. Let-7  miRNAs 
negatively regulate Ras, and are typical examples of 
miRNAs that are frequently downregulated in solid 
cancers such as lung, breast, gastric, colon cancers and 
pituitary adenomas and are considered as classical 
tumor suppressors genes [3-5]. In addition, loss of let-7 
expression can identify a less differentiated class of 
cancers, while, let-7a-2 low expression correlates with 
p o o r  s u r v i v a l  i n  l u n g  c a n c e r  p a t i e n t s .  A t  t h e  
transcriptional level MYCN activity is reported to 
result in the upregulation of let-7b levels in primary 
neuroblastoma [26]. Let-7 overexpression is reported to 
represses cell proliferation. Interestingly, let-7f is found 
to promote angiogenesis [26]. Chen et al., [31] reported 
that  let-7i is involved in epithelial responses against 
microbial infection. Let-7i is highly expressed in 
human cholangiocytes (biliary epithelial cells) and 
regulates TLR4 expression. Infection of these cells with 
Cryptosporidium parvum (parasite that causes 
intestinal and biliary diseases) results in the reduced 
expression of let-7i in a MyD88/NF-kB-dependent 
manner. 
miR-223 
Due to its expression almost exclusively in bone 
marrow this miRNA is considered myeloid-specific. 
An interplay between miR-223 and two transcription 
factors, NFI-A and C/EBP (CCAAT/enhancer-binding 
protein), was reported to play an important regulatory 
role in granulocyte formation and miR‑223 expression 
is shown to be under the control of C/EBP activity, a 
well known transcription factor with effects on 
granulopoiesis  [32]. The knockout mice for this 
miRNA proved the previous reports and confirmed 
that  miR-223 is a key player in granulocyte 
differentiation [33]. Thus in the absence of miR-223 an 
increase in the production, differentiation and 
activation of granulocytes was observed resulting in 
tissue inflammation and damage. These findings have 
important implications for the treatment of 
inflammatory conditions as well as leukemia. The 
study suggested Mefc2 transcription factor as being a 
target of miR-223 [33]. Due to the fact that many types 
of leukemia have reduced levels of miR-223, finding 
out how lost expression of this miRNA contributes to 
the development of leukemias represent the next area 
of study.  
miR-142  
miR-142, is located on chromosome 17, at a site of 
a translocation associated with aggressive B cell 
leukemia  [34, 35].  miR-142 is among the highest 
expressed miRNA in almost all the hematopoietic 
lineages, hematopoietic stem cells, T cells, B cells, and 
its expression varies also within the type of cell, 
depending on the activation state [9, 10]. There are not 
yet mouse models for this miRNA. However, finding 
out the transcription factors that control its expression 
and its mRNA target transcripts will bring more 
understanding for the oncogenic functions of this 
miRNA. In addition, manipulating the levels of this 
miRNA in aggressive B cell leukemias and monitoring 
its effects on proliferation, differentiation and 
apoptosis of these cells would be of great interest.  
miR- 15, -16 
miR-15 and miR-16 genes are often deleted or 
expressed at reduced levels in B cell chronic 
lymphocytic leukemias, hence the proposed function 
of tumor-suppressor genes [36, 37]. In addition, 
miR-15, -16 have been found to also be downregulated 
or deleted in lung and colorectal cancers [4, 29]. Bcl-2 is 
the first target described for these miRNAs [38]. It was 
reported that when these miRNAs are deleted or 
downregulated the levels of Bcl-2 increase, protecting 
the cells from apoptosis. Furthermore, both these Int. J. Med. Sci. 2008, 5 
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m i R N A s  w e r e  p r o p o s e d  t o  b e  i n v o l v e d  i n  
hematopoietic cell lineage differentiation [12]. 
miRNA-BASED GENE THERAPY? 
Most of the miRNAs that are reported to be 
necessary for the differentiation and function of 
immune cells are found to be abnormally expressed in 
both solid and liquid tumors. Thus the first miRNA 
microarray profiling reported by Calin et al.,  [11] 
showed significant differences between B cell chronic 
lymphocytic leukemia and normal CD5+ B cells. 
Furthermore, analyses of hematopoietic tissue specific 
miRNAs such as miR-142, 155, 181 and 223 in 
malignant hematopoietic cell lines showed that 
although they have similar pattern of expression 
compared to normal cell lineages, the levels of 
expression were significantly altered, suggesting for 
the important roles of these miRNAs in hematopoietic 
diseases specially leukemias/lymphomas [39].  
miRNA expression profiling studies suggested 
that miRNAs might be used as diagnostic, prognostic 
and therapeutic tools. Promising results have been 
obtained from studies of miRNAs on mammalian cell 
culture systems and animal in vivo models. miRNAs 
are natural antisense interactors that modulate the 
expression of multiple genes. The use of anti-miRNA 
oligonucleotides (antisense to the miRNA impairing 
the interaction between miRNAs and target mRNAs) 
in different cancer cell lines seems to be very 
promising techniques for modulating miRNA action. 
The same stands for the use of mimic miRNAs in order 
to reconstitute the expression of lost miRNAs in 
tumors. The development and in vivo use of 
"antagomirs", a novel class of chemically engineered 
oligonucleotides, showed that antagomirs are specific 
and effective silencers of miRNA expression in mice 
[40]. Antagomir technology can therefore be promising 
as therapeutic tools in many diseases, from metabolic 
disorders, to cancer and immune related diseases.  
CONCLUSION 
Discovered 15 years ago in C.elegans  [41], 
miRNAs play important roles in all the cellular 
processes studied so far and their deregulated 
expression is associated with different diseases 
including cancer or immunological disorders. Both 
increased and decreased expression of miRNAs is 
observed in neoplasias, and therefore the terms 
onco-miRNAs and tumour-suppressor-miRNAs are 
used [4, 5]. The mouse models developed so far for 
miRNAs primarily expressed in the hematopoietic 
lineages showed that miRNAs contribute in the 
development, differentiation and function of immune 
cells. These models showed to be important not only 
for analyzing miRNA function in vivo but also for 
future drug development. Overall we can conclude 
that miRNAs are lineage-specific and important 
components of hematopoitic lineage differentiation. 
When their expression is modified the harboring cells 
become prone to cancer or other diseases. 
miRNA-based gene therapy targeting deregulated 
miRNAs will be the future tool for gene therapy.  
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